Truist Securities also increased its price target for CVS Health to $76, citing the company's impressive fourth-quarter performance and strategic measures aimed at enhancing Health Benefit margins. BofA Securities followed suit, raising the price target to $75 and highlighting the strong potential for earnings growth driven by CVS's Aetna business unit. Meanwhile, Leerink Partners upgraded CVS Health's stock rating from Market Perform to Outperform, raising the price target to $75, emphasizing the stabilization of CVS's Aetna and Healthcare Benefits segments.